CATALYST PHARMACEUTICALS INC (CPRX)

US14888U1016 - Common Stock

15.11  -0.23 (-1.5%)

Buy % Consensus

86

ChartMill assigns a Buy % Consensus number of 86% to CPRX. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 27.39. This target is 81.3% above the current price.
CPRX was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about CPRX.
In the previous month the buy percentage consensus was at a similar level.
CPRX was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 15.1123.2326.5227.3935.70 - 53.74% 75.51% 81.30% 136.27%
Up and Down Grades
Date Firm Action Rating
2024-03-27 Oppenheimer Reiterate Outperform -> Outperform
2024-03-22 Cantor Fitzgerald Reiterate Overweight -> Overweight
2024-03-14 Cantor Fitzgerald Reiterate Overweight -> Overweight
2024-03-14 Citigroup Initiate Buy
2024-03-07 B of A Securities Initiate Buy
2024-03-01 Cantor Fitzgerald Maintains Overweight -> Overweight
2024-03-01 HC Wainwright & Co. Reiterate Buy -> Buy
2023-12-21 Oppenheimer Initiate Outperform
2023-08-22 Cantor Fitzgerald Reiterate Overweight -> Overweight
2023-08-11 Cantor Fitzgerald Maintains Overweight -> Overweight
2023-08-11 HC Wainwright & Co. Reiterate Buy -> Buy
2023-07-21 HC Wainwright & Co. Reiterate Buy -> Buy
2023-06-21 Cantor Fitzgerald Reiterate Overweight -> Overweight
2023-06-21 Truist Securities Maintains Buy
2023-06-20 Truist Securities Maintains Buy
2023-05-12 HC Wainwright & Co. Reiterate Buy -> Buy
2023-03-20 HC Wainwright & Co. Reiterate Buy
2023-01-19 Truist Securities Maintains Buy
2022-12-21 Truist Securities Maintains Buy
2022-12-21 HC Wainwright & Co. Maintains Buy
2022-12-20 Piper Sandler Maintains Overweight
2022-08-24 Roth Capital Downgrade Buy -> Neutral
2022-08-11 Truist Securities Maintains Buy
2022-08-11 HC Wainwright & Co. Maintains Buy
2022-02-08 HC Wainwright & Co. Maintains Buy
2021-03-18 Roth Capital Maintains Buy